3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
15
fludarabine
12
Mycophenolic Acid
10
Standard of Care
9
Whole-Body Irradiation
7
Tacrolimus
7
venetoclax
6
Specimen Handling
6
Sirolimus
6
Practice Guidelines as Topic
6
trametinib
5
Melphalan
5
fludarabine phosphate
4
Mesna
4
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Biopsy
4
Behavior Therapy
4
Azacitidine
4
Thiotepa
3
Peripheral Blood Stem Cell Transplantation
3
GSK2636771
3
Educational Status
3
Crizotinib
3
Busulfan
3
thymoglobulin
2
talquetamab
2
ruxolitinib
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
bexmarilimab
×
90 days
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled